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ABSTRACT
In Tunisia, dependence to high-dosage buprenorphine (HDB) is expanding since 
the uprising of 2011, driving the epidemics of blood-borne infections among people 
who inject drugs. Only one rehabilitation center (Thyna center), run by the Tunisian 
Association for the Prevention of Drug Use is still operating in the country and accepting 
to treat patients. The aim of this study is to provide evidence-based solutions for the 
mitigation and prevention of HDB illicit use in Tunisia through the analysis and discussion 
of the results of a cross-sectional survey conducted to describe the socio-economic, 
the medical characteristics, the substance use patterns, and the treatment outcomes 
of patients seeking treatment at the Thyna rehabilitation center during the year 2013. 
The results of this survey showed that main demographic characteristics of the patients 
using illegal HDB were single men, unemployed and from low-income urban areas. 
The intravenous use was privileged and incarceration recurrences (p<0.05), alcoholism 
(p<0.01) and migration (p<0.01) were associated with daily dosage of HDB. Most of the 
patients dropped out of treatment within the first month at the center. The analysis 
reveals the unmet needs of the people who inject drugs in terms of prevention and 
treatment and identifies opioid maintenance therapy within a psychosocial rehabilitation 
program framework as a good alternative to the current available health services for 
people who use drugs in Tunisia. Future research areas will explore the social factors 
behind substance use and substance injection in Tunisia among out-of reach groups of 
women and adolescents; as such data is needed to develop efficient policies. 
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Illicit drugs dependence has direct and 
indirect adverse consequences on indi-
viduals and on populations. In 2010, it 
was estimated to account for almost 1% 
of global all-cause Disability-Adjusted Life 
Years (DALY) (Degenhardt et al., 2013). 
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A particular aspect of drug dependence 
is Injecting Drug Use (IDU), mainly opi-
oids that derive from opium e.g. heroine, 
morphine. Opioid dependence is the larg-
est contributor to the global burden of 
disease causing 9.2 million DALY globally 
(Degenhardt et al., 2013). Countries with 
the highest burden are mainly countries 
in Europe and North America, nonethe-
less, recent reviews suggest that illicit 
substance use is quickly expanding across 
Africa and the Middle-East (Dewing, Plüd-
demann, Myers, & Parry, 2006). A litera-
ture review on IDU in six African countries 
showed that high-risk behaviors among 
people who inject drugs are potentially 
contributing to the spread of Human Im-
munodeficiency Virus (HIV) in the conti-
nent (Dewing et al., 2006). This high risk 
is imputable to direct transmission of 
the virus through the sharing of inject-
ing equipment, such as syringes (“People 
who inject drugs, HIV and AIDS,” 2015). 
Furthermore, IDU alone as a risk factor 
accounts for 2.1 million DALY globally (De-
genhardt et al., 2013) and is considered 
as an important factor driving the HIV 
epidemics in African countries (Horton & 
Das, 2010). 
Tunisia, a North African country, is no 
exception. While transmission of HIV 
in the general population is still limited, 
the highest infection rates are registered 
among high-risk groups such as people 
who inject drugs. In 2011, a study con-
ducted in Tunis, capital city of Tunisia, es-
timated that almost 25% of HIV infections 
are imputable to IDU and that 2.4% of 
people who inject drugs are HIV positive 
(Rahimi Movaghar, Amin Esmaeili, Aaraj, 
& Hermez, 2012). The Tunisian National 
AIDS Strategy includes people who inject 
drugs as a key target population. Yet, it is 
hard to assess the general prevalence of 
IDU in the country, and harm reduction 
and preventive services are solely pro-
vided by non-profit, private organizations 
(“Bénéficiaires principaux Sida,” n.d.). Fi-
nally, rehabilitation options are very lim-
ited in the public sector and Opioid Main-
tenance Therapy (OMT) medication are 
not available in Tunisia (Skhiri, Zalila, Zid, 
& Boukassoula, 2014).
OMT offers a long-term treatment of 
opioid dependence with replacement 
medication such as Methadone or High-
Dosage-Buprenorphine (HDB) to decrease 
the withdrawal syndrome after opioids 
cessation (Bart, 2012). Buprenorphine is a 
semi-synthetic opioid formulated in sub-
lingual, highly-dosed tablets to be pre-
scribed as part of OMT (Khanna & Pilla-
risetti, 2015). Although HDB is not legally 
accessible in Tunisia, neither in hospitals 
nor in pharmacies, the sub-lingual tablets 
could be obtained illegally on the black 
market since the early 2000. Back in 2008, 
a hospital-based study, described HDB in-
travenous use as “an emerging reality” in 
the Tunisian society (Becheikh, Ghachem, 
Zalila, & Boussetta, 2008). After the 2011 
Revolution, its trade and use have ex-
panded and have not been effectively ad-
dressed since (Belarbi et al., 2014). Today 
it is considered to be the first IDU sub-
stance (Skhiri et al., 2014).
Overall, drug use and injection are ex-
tremely criminalized by the law in Tunisia 
and people who inject drugs are marginal-
ized from the rest of the society (Rahimi 
Movaghar et al., 2012). Men and women 
who inject drugs also face limited treat-
ment options and insufficient prevention 
services, in addition to incarceration. Ef-
forts to mitigate and prevent are limited 
and coverage is low as only six free and 
safe needle exchange facilities exist on the 
national territory (Rahimi Movaghar et al., 
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2012). The growing non-medical and il-
licit use of HDB as a risk factor behind the 
growing hepatitis and HIV epidemics in 
Tunisia (Kilani et al., 2007; Mumtaz et al., 
2014), is a Public Health concern. Despite 
this reality, the legislation and national 
policies are lagging behind the emerging 
social trends. The few rehabilitation clin-
ics available in Tunis have shut down in 
recent years. Moreover, harm reduction 
centres and rehabilitation services de-
pend on external funding as they are not 
government-based. The political transi-
tion of 2011 has affected the development 
of their activities, and in some cases they 
were completely ceased. Only one reha-
bilitation center has been operating and 
accepting patients from all regions of the 
country (Skhiri et al., 2014). This center 
is managed by a non-governmental orga-
nization, the Tunisian Association for the 
Prevention of Drug Use, named ATUPRET 
and located in Thyna, near the city of Sfax.
METHODS
The main objectives of this survey are to 
describe the socioeconomic and medical 
characteristics, to identify the consump-
tion patterns and history of dependence, 
and to look at the correlated factors with 
HDB use and treatment outcomes of the 
patients seeking therapy for HDB depen-
dence at the above-mentioned rehabilita-
tion center. The aim is to use the results 
of the survey and provide evidence-based 
alternatives from the literature on mitigat-
ing the use of HDB in the Tunisian society. 
Participants
In this study, the population sample 
solely includes patients aged at least 18 
years old, and admitted for the treatment 
of HDB dependence between January 1st 
2013 and December 31st 2013 at the re-
habilitation center. A total of 167 subjects 
met these criteria and their records were 
retrieved.
Data collection
The data collection took place at the cen-
ter between January and March of 2014 
after gaining access to the archived medi-
cal records of the year 2013, with an ethi-
cal waiver from the association’s executive 
board. After consultations with the medical 
experts and psychologists at the center, a 
data collection form was developed by the 
authors with respects to anonymity and 
confidentiality. The form helped collecting 
personal information related to the objec-
tives of this survey. Relevant data included 
the socioeconomic variables e.g. gender, 
age, level of education, work and family 
status, the family history of substance use 
disorders, the individuals’ experience of ini-
tiation of substance use, the dosages and 
means of HDB daily self-administration. 
Blood-borne infections such as hepatitis C 
and HIV were reported as part of the medi-
cal history. The length of the stay at the 
clinic and the number of previous rehabili-
tation admissions, were collected to report 
on treatment outcomes.
Statistical Analysis
The information extracted was classi-
fied and codified into variables. The free 
software R-GUI was used for the statis-
tical analysis. Frequencies, ranges and 
standard deviations were determined 
for socioeconomic characteristics and for 
variables related to HDB consumption. A 
chi-square statistical test was conducted 
for variables related to the daily dosage 
of HDB and to the duration of HDB intake. 
Subsequently, a Kendall non-parametric 
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test was run to identify the correlated 
variables in the sample.
RESULTS
Patients admitted for HDB dependency 
in 2013 presented 54% of all the patients 
admitted that year.
Socioeconomic characteristics
All patients were men and the mean 
age was 33.5 ± 8.1 years with 95% be-
tween 32 and 35 years old. The popula-
tion characteristics are summarized in 
Table 1. Among the patients, 73% were 
single, 60% were unemployed and 51% 
had completed their primary education 
or less. The majority of the population 
(94%) was living in urban areas and 35% 
came from large families (more than 
three siblings). More than a quarter (28%) 
experienced domestic violence and 20% 
were orphaned at a young age. Family his-
tory defined as having any family member 
with history of substance use disorders 
was reported for 16%. Furthermore 40% 
had migrated, mainly to European coun-
tries (34%), either legally or through ille-
gal ways. Incarceration rate was at 68% 
with 44% recidivism rate after the first 
confinement.
Medical history
On the 167 medical records, 54 indi-
cated infection with hepatitis C, 14 with 
hepatitis B and 13 reported HIV-positive 
cases. Among the HIV-positive group, 12 
also suffered from hepatitis C (cases of 
double infection).
History and initiation of substance use
The mean age for the first consumption 
of a psychoactive substance, was 16.4 ± 
4.5 years and the mean age for the first 
injection of an opioid was 24.0 ± 6.1 years. 
Many subjects initiated drug use by taking 
multiple products at the same time. For 
about half (53%), marijuana was the first 
recreational consumption and for almost 
the fifth (18%) it was diverted psychotro-
pic medicine such as benzodiazepines. 
Furthermore, a small proportion of 8% 
reported glue or other inhalants sniffing 
before the age of ten years old, whereas 
use of heroin and cocaine as the first rec-
reational drug was in only 7% of the cases 
and HDB for a few 2% (Figure 1).
Self-reported causes of initiation were 
related to peer-pressure in 25%, to feelings 
of curiosity and thrill-seeking in 21%, in 
order to escape a harsh reality in 22% and 
within the illegal emigration context for 
16% of the cases. A specific reason for using 
HDB was the abundance of the substance 
and the facility of finding and procuring it 
in comparison to other products such as 
Heroine, which was the case for 13% of the 
sample. Less than 1% reported that they 
have developed an opioid dependence af-
ter using prescribed pain killers which led 
them to the use of DB as a replacement.
Multiple consumptions
Apart from regularly injecting HDB, the 
majority of the population (98%) was us-
ing multiple other dependence-producing 
substances simultaneously. Harmful alco-
hol use affected 78% and alcoholism 22%. 
Tobacco and Marijuana smoking rates were 
at 86% and 70%, respectively. Moreover, di-
version of psychotropic medicine was com-
mon with benzodiazepines used by 60% 
and anxiolytic drugs by 43% of the subjects.
Patterns of HDB intake
The daily intake and dosage of HDB 
were reported in the medical records in 
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Table 1. Demographic characteristics and substance use initiation variables
Ages (Years): Mean (±SD) Mean
Age 33,5(±8,1)
Age At First Substance Use 16,4 (±4,5)
Age At First Substance Injection 24,0 (±6,1)
Mean Duration Of HDB Use 7,5 (±3,7)









Primary School 85 51%
Secondary/High School 66 40%
High School Graduate 13 8%
University 3 2%
Family Environment Number Percentage
Parent(S) Deceased 33 20%
Domestic Violence As A Child 46 28%
Large Family 59 35%
Family History Of Substance Use 26 16%
Profession Number Percentage
Unemployed 101 61%
Precarious Worker 31 19%
Salarial Work 35 21%
Migration Number Percentage
Emigrated 66 40%
Lived In European Country 56 34%
Illegal Migration 33 20%
Legal Migration 33 20%
Detention Number Percentage
Incarcerated At Least Once 113 68%
Multiple Incarcerations 74 44%
Drug-Related Felonies 73 44%
Demographic characteristics of the sample of 167 patients show the number and the percentage for each variable. The 
highest rates are related to being single and unemployed, having a low education level, living in urban areas, and having 
being incarcerated at least once.
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terms of multiples of eighth (1/8) of a 
tablet. In fact, this is how the patients re-
ferred to their consumption: one tablet 
was typically cut in 8, sold and consumed 
in such portions. For the sake of clarity 
and consistency, the dosage of daily intake 
was directly calculated from the medical 
records then reported in milligrams, con-
sidering that a tablet contains 8mg of HDB 
as it is the most common form of diverted 
HDB in the country (Skhiri et al., 2014). 
The mean dosage of daily intake was 6.5 
± 3.8 mg per day. The mean number of 
daily intakes was 3.7±2 times a day and 
the mean duration of HDB long-term use 
was evaluated to 7.5 ± 3.7 years.
Less than 1% of the patients used HDB 
via the sub-lingual route. Almost 70% 
started HDB intake through intravenous 
route and more than a quarter (26%) 
started HDB consumption through the 
intranasal route or “sniffing”. At the time 
of admission to the clinic, the majority of 
the sample (96%) was self-administrating 
HDB through intravenous syringe use, in 
opposition to 4% who have not transi-
tioned from sniffing yet.
Treatment and treatment outcome
The mean length of stay at the center 
was 16.8 ±8.3 days. About 47% of the 
medical records indicated that the patient 
had undergone at least another previous 
withdrawal management therapy.
Statistical Analysis
The chi-square test revealed that in-
carceration recidivism (p<0.05), alcohol 
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Figure 1. Substance used as the first recreational substance
Note: Initiation of substance use may start with one, two or more concomitant consumptions. Marijuana is the most 
popular substance to be used at the first time, followed by alcohol and psychotropic medicines that include tranquilizers 
and sedatives. Smaller proportions of the subjects used inhalants such as sniffing glue, and even less used heroin or 
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dependence (or alcoholism) (p<0.01) and 
migration (p<0.01) were associated with 
the daily dosage of HDB. In addition, du-
ration of HDB consumption was signifi-
cantly related to marital status (p<0.01), 
past heroin dependence (p<0.01) and al-
cohol dependence (Table 2). A correlation 
was established between the place of liv-
ing and the self-reported causes of HDB 
use (p<0,05).
Kendall non-parametric test showed 
that the daily dosage was positive-
ly correlated to the number of daily 
intakes(r=0.33, p<0.01) and to the long-
term HDB intake (r=0.18, p<0.01). A posi-
tive correlation between the early onset 
of substance use and the early onset of 
substance injection was also found but 
not significant (r=0.08, p=0.2). Finally, an-
other positive correlation was revealed 
between the age of the subject and HDB 
consumption duration (r=0.39, p<0.01).
DISCUSSION
Through the analysis and discussion of 
the results and identification of the un-
met needs of patients at the rehabilita-
tion center, this study aims at providing 
evidence-based alternatives and solu-
tions to prevent HDB use and mitigate its 
consequences in Tunisia. 
The results showed that the majority of 
HDB users seeking help at the center are 
young adult men, single, unemployed, 
and with low educational level. Although 
the center did not use any selection cri-
teria and accepted patients from all over 
the country, the majority of the sample 
came from urban areas. These findings 
are similar to other reports that have 
stated that trafficking of this substance 
occurs in low-income urban settings 
among groups of young unemployed 
men with history of criminal cases (Skh-
iri et al., 2014). Other research studies 
have consistently portrayed comparable 
aspects of people who inject drugs in 
Tunisia, as well (Becheikh et al., 2008; 
Belarbi, Ben Ammar, Moula, Bouasker, & 
Ghachem, 2013; Robbana, Moula, Guer-
mani, Bouasker, & Ghachem, 2013). The 
social stigma around IDU has amplified 
through its consistent portrayal in rela-
tion to criminality in major published 
studies and official reports. Consequent-
ly, other groups such as adolescents and 
women with substance use disorders 
become harder to reach and include in 
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Table 2. Consumption of high-dosage buprenorphine
A+ A- χ2 P H+ H- χ2 P E+ E- χ2 P I>2 I<1 χ2 P Single Married χ2 p



































































































Note: A+ Reported alcohol addiction ; A- No reported alcohol addiction; H+ Reported heroin addiction; H- No reported 
heroin addiction; E+ Have emigrated; E- Have never emigrated; I>2 Have been incarcerated more than once; I<1 Have 
been incarcerated once or never.
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research studies as they fear stigma or 
other social or legal consequences. 
About 70% of the patients had a crimi-
nal record with drug-related felonies in 
more than 50% of them. Findings also 
indicated long periods of custody and 
frequent recidivism. High incarceration 
rates have also been reported by Dakhlia 
et al. and Robbana et al. in their studies 
on smaller samples of patients with HDB 
dependence admitted in public hospitals 
(Dakhlia Boukhari & Zalila, 2010; Robbana 
et al., 2013). Nevertheless, HDB was de-
picted in the literature to be considered 
by people who inject drugs as a “safer” 
substance to use in order to avoid crimi-
nal convictions, since it is not detectable 
through forensic investigations (Skhiri et 
al., 2014). The high rates of drug-related 
felonies in the survey sample may be re-
lated to the use of other substances in 
concomitance with HDB or in the past at 
the initiation of recreational substance 
use. 
A study conducted in Singapore, stated 
that 80% of people who injected HDB 
served a prison sentence (Winslow, Ng, 
Mythily, Song, & Yiong, 2006). Both Sin-
gapore and Tunisia have strong legisla-
tion governing substance use. In Tunisia, 
non-medical consumption of opioids and 
other drugs is criminalized (Narcotics 
Law n° 92-52, 18th May 1992) and treat-
ments of opioid addiction are not avail-
able in prisons. Apart from hindering the 
work of harm reduction programs, such 
strong laws doubled with strict moral so-
cial norms constrain people who inject 
drugs and dissuade them from coming 
forward to seek medical care and social 
assistance. Furthermore, HDB consump-
tion was correlated to migration among 
the study sample. Both Becheikh et al. 
in 2008, and Robbana et al. in 2013, 
also reported in their respective stud-
ies high rates of illegal migration to Eu-
ropean countries, among a subgroup of 
people who inject HDB with a history of 
heroin addiction. The subgroup of HDB 
users who have lived in European coun-
tries have first encountered HDB during 
a prescribed OMT to treat their heroine 
dependence. Illegal use of HDB later on 
in life, and in places where OMT is not a 
legally available therapeutic option, is an 
attempt to self-manage a long-term opi-
oid dependence. 
The circumstances and rationales of 
HDB use in Tunisia, where it is illegally 
sold in the black market, are different 
from other countries where it can be le-
gally procured within an OMT framework. 
In fact, the self-reported causes of HDB 
initiation were correlated to the place of 
living. In Italy, younger opioid consumers 
were reported to be more likely to divert 
HDB (Moratti, Kashanpour, Lombardelli, 
& Maisto, 2010), while in Sweden a study 
showed that buprenorphine was typi-
cally used at a later stage or at a severe 
level of opioid dependence (Johnson & 
Richert, 2015) as an attempt to self-treat 
withdrawal or to manage pain (Cicero, El-
lis, Surratt, & Kurtz, 2014). These studies 
occurred in countries where HDB is legally 
available, which is not the case in Tunisia 
where HDB is not perceived as a medica-
tion but rather as an illegal, recreational, 
and dependence-producing substance. 
HDB has never been introduced as a 
treatment option in any sanitary struc-
tures; and Tunisian healthcare profession-
als have not been trained to prescribe it. 
Therefore, even though the rationales be-
hind the illicit use of HDB in Europe and in 
Tunisia can be similar, the patterns of self-
administration and dependence stages 
are different. 
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The initiation of injection of a de-
pendence-producing substance among 
people who already use it through other 
routes, is a complex phenomenon involv-
ing a wide range of biological, socioeco-
nomic and psychological factors such as 
peer-pressure (Goldsamt, Harocopos, Ko-
brak, Jost, & Clatts, 2010). Ability to use 
less of an opioid or tolerance to different 
modes of administration can also, lead 
to initiating intravenous intake. The cor-
relation found between the daily dosage 
of HDB and the number of daily intakes 
demonstrates the biological tolerance 
phenomenon that is particular to opioids 
and leads the user to increase the dos-
age or resort to a quicker intake route, 
in order to obtain the same effect of the 
substance. In fact, nearly all patients tran-
sitioned to injecting the substance per 
intravenous, after starting with intranasal 
administration. Peer-pressure, affluence 
and availability of HDB despite its illegal 
characteristic, were self-reported reasons 
for the initiation of injection of the sub-
stance. HDB is indeed considered to be a 
widely available and cheaper opioid than 
other illegal opioids on the black market 
(Skhiri et al., 2014). 
On another note, 98% of the sample re-
ported concomitant consumption of one 
or multiple other recreational, depen-
dence-producing substances next to HDB. 
In a 2012 survey conducted by the Center 
for Urgent Medical Assistance of Tunis, 
92% of HDB users co-administered other 
substances at the same time which the 
authors labeled as poly-consumption (Ben 
Salah & Hamouda, 2013). The most com-
mon psychotropic compounds used with 
HDB being benzodiazepines and alcohol, 
these associations may become very dan-
gerous and may lead to fatalities (Häkkin-
en, Launiainen, Vuori, & Ojanperä, 2012). 
Anxiolytic medications, sought for their 
tranquilizing effects, also have a major di-
version and dependence potential. Poly-
consumption challenges the therapeutic 
management as it is complex to tackle 
numerous addictions simultaneously. The 
length of the treatment at Thyna center 
for dependence was approximately two 
weeks, indicating a high drop-out rate and 
poor health outcomes. Derbel et al. eval-
uated the outcomes of the medical man-
agement of patients admitted at Thyna 
center and concluded that the symptom-
atic care of the withdrawal symptoms had 
limited and poor outcomes (Derbel, Ghor-
bel, Akrout, & Zahaf, 2016). Alternatively, 
maintenance therapy can be a beneficial 
tool to optimize treatment outcomes.
In addition, high rates hepatitis C and 
HIV-hepatitis C double infections were 
registered, illustrating the role of HDB 
injection and high-risk behaviors as risk 
factors behind the expansion of HIV and 
hepatitis among people who inject drugs 
in Tunisia (Belarbi et al., 2013). In a hospi-
tal-based study, 78% of HIV-positive inpa-
tients had history of substance injection 
(Kilani et al., 2007). Numerous preventive 
public health interventions in Tunisia, such 
as the unlimited selling of sterile syringes 
over the counter in community pharma-
cies, are strategic to face the expansion of 
blood-borne infections but remain insuffi-
cient. Modern health policies are needed 
to democratize the harm-reduction facili-
ties and improve their accessibility. 
Providing affordable and safe HDB was 
established as an effective strategy to limit 
its diversion (Lofwall & Walsh, 2014). Poli-
cies that facilitate access to therapeutic 
options for opioid users were proven to 
be better solutions than constrained sub-
stance use policies. Relaxed legislation and 
OMT treatment options have been proved 
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to have positive outcomes and were asso-
ciated with not only an improved quality 
of life, but also with a better social reha-
bilitation of the people who inject drugs 
and with positive effects on their families 
and social networks as well (Bart, 2012). 
In France, the marketing of HDB as a treat-
ment for opioid dependence, proved to 
bring major public health benefits (Fats-
eas & Auriacombe, 2007). Sun. et al meta-
analysis looked at the OMT experience in 
China and concluded that it is an effec-
tive tool for the successful rehabilitation 
of opioids’ users (Sun et al., 2015). In the 
light of this available evidence about the 
importance of OMT, implementation of 
modern and patient-centered therapeutic 
options coupled with responsive and Hu-
man Rights-based drug policies in Tunisia, 
will help to lower the high incarceration 
rates and poor treatment outcomes de-
picted in the results. Tailored long-term 
replacement and maintenance medica-
tion treatment with simultaneous psycho-
therapy are effective to prevent relapses, 
lower blood-borne infection risks, pro-
mote social reinsertion and improve gen-
eral quality of life (Carrieri et al., 2006). In-
troducing OMT in Tunisia will help reduce 
the illegal use of HDB and its consequenc-
es on a broader scale. 
OMT medications (HDB and Metha-
daone) were enlisted on the WHO list of 
essential medicines since 2005(Herget, 
2005). Yet, in 2018 they are not legally ac-
cessible to the patients who need them in 
Tunisia. Introducing OMT could prove to 
be a multi-fold scheme that will encom-
pass various sectors. However, successful 
experiences from other middle-income 
countries have been extensively docu-
mented and evidence-based guidelines 
are available. To carry-out OMT in Tunisia, 
training and technical support to health-
care providers and social workers will be 
necessary to equip them with the neces-
sary tools.
CONCLUSION
Opioid diverted use has been largely 
documented in North Africa and particu-
larly in Tunisia under the umbrella of HIV 
prevention programs. However, all reports 
align with this survey showcasing a homog-
enous group of single and unemployed 
men with criminal records with substance 
use disorders, seldom portraying out-of-
reach groups such as women and adoles-
cents who inject drugs. Despite the alarm-
ing expansion of substance use disorders 
and its public health repercussions since 
the 2011 uprising, therapeutic and preven-
tive solutions are still limited in Tunisia. 
The social factors surrounding HDB depen-
dence are yet to be explored. Evidence-
based policies such as OMT are paramount 
to improve the current situation, rehabili-
tate the alarming growing number of HDB 
users, and reverse the trends. Advocacy for 
introducing OMT in Tunisia should be sup-
ported as a Human Rights-based approach 
and an efficient alternative to the existing 
withdrawal management therapy.
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